OPT Key Statistics, Chart & Performance
The current stock price of OPT is 3.41 USD. In the past month the price decreased by -34.55%. In the past year, price decreased by -1.16%.
OPT Latest News, Press Relases and Analysis
OPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About OPT
Company Profile
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Company Info
OPTHEA LTD-SPON ADR
Suite 0403, Level 4, 650 Chapel Street, South Yarra
Melbourne VICTORIA 3141 AU
CEO: Megan Baldwin
Employees: 33
Phone: 61398260399
OPTHEA LTD-SPON ADR / OPT FAQ
Can you describe the business of OPTHEA LTD-SPON ADR?
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
What is the current price of OPT stock?
The current stock price of OPT is 3.41 USD. The price increased by 7.23% in the last trading session.
Does OPTHEA LTD-SPON ADR pay dividends?
OPT does not pay a dividend.
How is the ChartMill rating for OPTHEA LTD-SPON ADR?
OPT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists OPT stock?
OPT stock is listed on the Nasdaq exchange.
What is the ownership structure of OPTHEA LTD-SPON ADR (OPT)?
You can find the ownership structure of OPTHEA LTD-SPON ADR (OPT) on the Ownership tab.
What is the outstanding short interest for OPTHEA LTD-SPON ADR?
The outstanding short interest for OPTHEA LTD-SPON ADR (OPT) is 0.37% of its float.
OPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OPT. When comparing the yearly performance of all stocks, OPT turns out to be only a medium performer in the overall market: it outperformed 59.46% of all stocks.
OPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPT. OPT may be in some trouble as it scores bad on both profitability and health.
OPT Financial Highlights
Over the last trailing twelve months OPT reported a non-GAAP Earnings per Share(EPS) of -2. The EPS increased by 16.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPT Forecast & Estimates
10 analysts have analysed OPT and the average price target is 6.57 USD. This implies a price increase of 92.75% is expected in the next year compared to the current price of 3.41.
For the next year, analysts expect an EPS growth of 56.03% and a revenue growth -37% for OPT